Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC announces strategic respiratory transaction with Almirall


Wednesday, 30 Jul 2014 02:02am EDT 

AstraZeneca PLC:Says agreement to transfer to the company the rights to Almirall's respiratory franchise for an initial consideration of $875 mln on completion, and up to $1.22 bln in development, launch, and sales-related milestones.Says it will own the rights for the development and commercialisation of Almirall's existing respiratory business, including rights to revenues from Almirall's existing partnerships, as well as its pipeline of investigational therapies.Under the agreement, Almirall Sofotec, an Almirall subsidiary focused on the development of devices, will also transfer to AstraZeneca.